[go: up one dir, main page]

PE20240808A1 - Composiciones, metodos y sistemas para la administracion de farmacos en aerosol - Google Patents

Composiciones, metodos y sistemas para la administracion de farmacos en aerosol

Info

Publication number
PE20240808A1
PE20240808A1 PE2024000058A PE2024000058A PE20240808A1 PE 20240808 A1 PE20240808 A1 PE 20240808A1 PE 2024000058 A PE2024000058 A PE 2024000058A PE 2024000058 A PE2024000058 A PE 2024000058A PE 20240808 A1 PE20240808 A1 PE 20240808A1
Authority
PE
Peru
Prior art keywords
methods
refers
aerosol
drugs
administration
Prior art date
Application number
PE2024000058A
Other languages
English (en)
Inventor
Vidya Joshi
James Archbell
Kellisa Lachacz
Charina Lampa
Lauren Mello
Gertrude Gutierrez
David Lechuga-Ballesteros
Penny Tan
Michael RIEBE
Original Assignee
Astrazeneca Pharmaceuticals Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=82748203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20240808(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Pharmaceuticals Lp filed Critical Astrazeneca Pharmaceuticals Lp
Publication of PE20240808A1 publication Critical patent/PE20240808A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Refiere a una composicion farmaceutica administrable desde un inhalador de dosis medida, la cual comprende un propulsor de grado farmaceutico (1E)-1,3,3,3-Tetrafluoro-1-propeno (HFO-1234ze(E)) con una pureza aproximada de 99,90 %; una o mas especies de agente activo seleccionados de un antagonista muscarinico de accion prolongada (LAMA) como glicopirrolato, o un agonista ?2 de accion prolongada (LABA) como formoterol; y particulas de fosfolipidos que comprenden microestructuras perforadas que comprenden 1,2-diestearoil-sn-glicero-3-fosfocolina (DSPC) y cloruro de calcio. Asimismo, refiere al uso de dicha composicion farmaceutica en la fabricacion de un medicamento para el tratamiento de asma o COPD y metodos para el tratamiento.
PE2024000058A 2021-07-09 2022-07-08 Composiciones, metodos y sistemas para la administracion de farmacos en aerosol PE20240808A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163220362P 2021-07-09 2021-07-09
US202163282356P 2021-11-23 2021-11-23
PCT/US2022/036542 WO2023283438A1 (en) 2021-07-09 2022-07-08 Compositions, methods and systems for aerosol drug delivery

Publications (1)

Publication Number Publication Date
PE20240808A1 true PE20240808A1 (es) 2024-04-18

Family

ID=82748203

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2024000057A PE20240807A1 (es) 2021-07-09 2022-07-08 Composiciones, metodos y sistemas para la administracion de farmacos en aerosol
PE2024000056A PE20241067A1 (es) 2021-07-09 2022-07-08 Composiciones, metodos y sistemas para la administracion de farmacos en aerosol
PE2024000058A PE20240808A1 (es) 2021-07-09 2022-07-08 Composiciones, metodos y sistemas para la administracion de farmacos en aerosol

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2024000057A PE20240807A1 (es) 2021-07-09 2022-07-08 Composiciones, metodos y sistemas para la administracion de farmacos en aerosol
PE2024000056A PE20241067A1 (es) 2021-07-09 2022-07-08 Composiciones, metodos y sistemas para la administracion de farmacos en aerosol

Country Status (28)

Country Link
US (5) US20240358662A1 (es)
EP (6) EP4393478A3 (es)
JP (3) JP2024527348A (es)
KR (3) KR20240042436A (es)
AU (3) AU2022305962A1 (es)
CA (3) CA3226153A1 (es)
CL (3) CL2024000041A1 (es)
CO (3) CO2024000631A2 (es)
CR (3) CR20240064A (es)
DK (3) DK4197528T3 (es)
DO (3) DOP2024000004A (es)
EC (1) ECSP24011022A (es)
ES (3) ES2981514T3 (es)
FI (3) FI4175620T3 (es)
HR (3) HRP20240753T1 (es)
HU (3) HUE067281T2 (es)
IL (3) IL309888A (es)
LT (3) LT4197528T (es)
MA (3) MA60223B1 (es)
MX (3) MX2024000465A (es)
PE (3) PE20240807A1 (es)
PL (3) PL4175620T3 (es)
PT (3) PT4175620T (es)
RS (3) RS65598B1 (es)
SI (3) SI4197528T1 (es)
SM (3) SMT202400312T1 (es)
TW (3) TW202317079A (es)
WO (3) WO2023283438A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4514358A1 (en) * 2022-04-28 2025-03-05 AstraZeneca AB Combination of albuterol and budesonide for the treatment of asthma

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37872A (en) 1863-03-10 Improved mast-hoop
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (es) 1972-05-19 1975-08-18 Bofors Ab
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
CA1201114A (en) 1980-02-15 1986-02-25 Gordon H. Phillipps Androstane carbothioates
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6136346A (en) 1995-04-14 2000-10-24 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5886200A (en) 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
NZ500555A (en) 1999-08-02 2000-11-24 Hovione Int Ltd Process for the preparation of mometasone furoate
WO2001032144A1 (en) 1999-10-29 2001-05-10 Inhale Therapeutic Systems, Inc. Dry powder compositions having improved dispersivity
MXPA02001323A (es) 2000-05-10 2004-07-16 Alliance Pharma Microgranulos con base fosfolipida para la liberacion de farmaco.
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
DE08020700T1 (de) 2002-10-25 2009-08-13 Honeywell International Inc. Zusammensetzungen mit fluorosubstituierten Olefinen
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
DK1606261T3 (da) 2003-03-10 2010-01-18 Nycomed Gmbh Hidtil ukendt fremgangsmåde til fremstilling af roflumilast
KR20060015316A (ko) 2003-05-28 2006-02-16 넥타르 테라퓨틱스 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법
US9308199B2 (en) 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
EP1904219A4 (en) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc METHOD FOR FORMING PARTICLES
CN100560598C (zh) 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
EP2435025B1 (en) 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Respiratory delivery of active agents
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CN103687483A (zh) * 2011-05-17 2014-03-26 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
CN104080770A (zh) 2011-11-09 2014-10-01 迈兰实验室有限公司 用于制备罗氟司特的改进方法
CN107596518B (zh) * 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
JP6153618B2 (ja) 2012-10-17 2017-06-28 インテルキム、ソシエダッド アノニマ ロフルミラストを調製するための方法
KR20200105983A (ko) * 2013-01-28 2020-09-09 인코젠 쎄라퓨틱스 프라이빗 리미티드 로플루밀라스트 n- 옥사이드의 흡입에 의한 자가면역, 호흡 및 염증성 장애의 치료방법
US20150150787A1 (en) * 2013-05-22 2015-06-04 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents
IL273713B2 (en) 2017-10-09 2023-10-01 Pearl Therapeutics Inc Drug delivery systems and related methods

Also Published As

Publication number Publication date
ES2981709T3 (es) 2024-10-10
MA60224B1 (fr) 2024-06-28
SI4175619T1 (sl) 2024-08-30
IL309908A (en) 2024-03-01
AU2022308837A1 (en) 2024-01-25
SI4175620T1 (sl) 2024-08-30
IL309888A (en) 2024-03-01
ES2981514T3 (es) 2024-10-09
CO2024000631A2 (es) 2024-02-15
CA3226557A1 (en) 2023-01-12
CA3226153A1 (en) 2023-01-12
EP4393477A2 (en) 2024-07-03
KR20240042438A (ko) 2024-04-02
SMT202400312T1 (it) 2024-09-16
DK4175619T3 (da) 2024-05-06
EP4366695A1 (en) 2024-05-15
PT4175620T (pt) 2024-06-21
EP4175619B1 (en) 2024-04-10
SMT202400370T1 (it) 2024-11-15
FI4175619T3 (fi) 2024-05-28
DOP2024000005A (es) 2024-04-15
HRP20240716T1 (hr) 2024-08-30
CR20240063A (es) 2024-04-25
CL2024000037A1 (es) 2024-08-16
CR20240064A (es) 2024-09-02
CA3226155A1 (en) 2023-01-12
FI4175620T3 (fi) 2024-06-25
TW202317079A (zh) 2023-05-01
SMT202400368T1 (it) 2024-11-15
US20240252440A1 (en) 2024-08-01
MX2024000468A (es) 2024-04-05
EP4175619A1 (en) 2023-05-10
US20230026203A1 (en) 2023-01-26
KR20240042436A (ko) 2024-04-02
CO2024000742A2 (es) 2024-02-26
LT4175620T (lt) 2024-06-25
LT4175619T (lt) 2024-06-10
KR20240042437A (ko) 2024-04-02
RS65597B1 (sr) 2024-06-28
ES2983201T3 (es) 2024-10-22
SI4197528T1 (sl) 2024-08-30
HRP20240753T1 (hr) 2024-09-13
PE20240807A1 (es) 2024-04-18
MA60223B1 (fr) 2024-06-28
CR20240066A (es) 2024-04-12
DK4175620T3 (da) 2024-06-03
US20240358662A1 (en) 2024-10-31
LT4197528T (lt) 2024-06-10
EP4393478A3 (en) 2024-09-11
HUE067281T2 (hu) 2024-10-28
MA61888B1 (fr) 2024-06-28
AU2022305962A1 (en) 2024-01-25
JP2024527348A (ja) 2024-07-24
WO2023283438A1 (en) 2023-01-12
ECSP24011022A (es) 2024-03-01
PL4175619T3 (pl) 2024-08-05
HUE067283T2 (hu) 2024-10-28
DK4197528T3 (da) 2024-05-06
DOP2024000004A (es) 2024-04-15
HUE067547T2 (hu) 2024-10-28
WO2023283441A1 (en) 2023-01-12
CL2024000039A1 (es) 2024-08-16
RS65537B1 (sr) 2024-06-28
PL4197528T3 (pl) 2024-08-12
JP2024525567A (ja) 2024-07-12
PT4175619T (pt) 2024-06-06
PL4175620T3 (pl) 2024-08-05
MX2024000465A (es) 2024-04-05
EP4393478A2 (en) 2024-07-03
TW202317081A (zh) 2023-05-01
EP4175620A1 (en) 2023-05-10
DOP2024000006A (es) 2024-04-15
EP4393477A3 (en) 2024-09-11
RS65598B1 (sr) 2024-06-28
TW202317080A (zh) 2023-05-01
EP4197528B1 (en) 2024-04-03
CO2024000748A2 (es) 2024-02-26
FI4197528T3 (fi) 2024-05-24
CL2024000041A1 (es) 2024-08-16
WO2023283439A1 (en) 2023-01-12
MX2024000467A (es) 2024-04-05
EP4175620B1 (en) 2024-04-10
HRP20240725T1 (hr) 2024-08-30
PT4197528T (pt) 2024-06-06
US20240325298A1 (en) 2024-10-03
EP4197528A1 (en) 2023-06-21
PE20241067A1 (es) 2024-05-13
IL309907A (en) 2024-03-01
US20240252432A1 (en) 2024-08-01
AU2022306682A1 (en) 2024-01-25
JP2024525555A (ja) 2024-07-12

Similar Documents

Publication Publication Date Title
ECSP088653A (es) Formulacion farmacéutica para aerosoles con dos o más principios activos y al menos una sustancia tensoactiva
AR101593A2 (es) Formulación superfina de formoterol
AR038641A1 (es) Formulacion superfina de formoterol
PE20121396A1 (es) Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol
PE20080204A1 (es) Formulaciones farmaceuticas que comprenden un anticolinergico y un beta agonista
PE20091672A1 (es) Nueva dosificacion y formulacion
BRPI0602430A (pt) composição medicinal, inalador para composição medicinal, método de tratamento de um mamìfero, recipiente do tipo capaz de conter a pressão de vapor de um propelente contido em seu interior e adicionalmente contendo uma composição medicinal adequada para administração a um mamìfero, método de produzir uma formulação aerossol adequada para transferência aos pulmões de um mamìfero por inalação
AR018410A1 (es) Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron
RS52940B (en) PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
AR057180A1 (es) Formulacion farmaceutica de absorcion oral que comprende insulina, entre otros, y su metodo de administracion
PE20160155A1 (es) Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
AR123674A2 (es) Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona
CL2023000998A1 (es) Formulación farmacéutica para inhalador presurizado de dosis medidas
BRPI0515103A (pt) composição farmacêutica, inalador, processos para preparar o mesmo, e uma composição farmacêutica, e, uso de uma composição farmacêutica
WO2017091767A3 (en) Drug formulations for cancer treatment
MX2015014513A (es) Composicion que comprende sulfato de salbutamol.
AR100368A1 (es) Tratamiento de trastornos respiratorios
PE20240808A1 (es) Composiciones, metodos y sistemas para la administracion de farmacos en aerosol
CO6220945A2 (es) Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma
PE20011271A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
BRPI0607172A2 (pt) método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos
AR091161A1 (es) Composicion farmaceutica para inhalacion, metodo, uso
AR040450A1 (es) Formulacion superfina de salmeterol